GT201 Injection For The Treatment Of Advanced Solid Tumors

Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional "3+3" dose-escalation principle,The second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.

NCT Number	NCT06144671
Lead Sponsor	Grit Biotechnology
Conditions	Solid Tumor, Adult
Enrollment	18 participants
Start Date	2023-09-13
Primary Completion	2026-09-13 (estimated)
Study Completion	2026-09-13 (estimated)
Updated on ClinicalTrials.gov	2026-04-27